43 results
Approved WMORecruiting
Part 1: dose safety confirmationPrimary: To evaluate the proportion of participants with TRAEs leading to discontinuation within 12 weeks after the first dose of nivolumab plus2 different dose levels of relatlimab (360 mg and 720 mg) in combination…
Approved WMORecruiting
To compare two (standard) treatment regimens in patients with KRAS mutated advanced stage NSCLC as first line treatment.
Approved WMORecruiting
Main Objective : - Dose escalation part: To determine the recommended phase 2 dose (RP2D) of Debio 0123 when administered in combination with carboplatin in subjects with solid tumors which recurred or progressed after prior cisplatin or carboplatin…